Precision Medicine
Integrated Oncology is an integral part of LabCorp that brings together world-class diagnostics and drug development capabilities so patients have day one access to companion diagnostics and associated FDA approved therapies. Together, we are uniquely positioned at the intersection of research and patient care to enable more precise and individualized health care. Our menu of molecular, next generation sequencing and immuno-oncology assays are at the forefront of precision medicine, matching the right patient with the best treatment.
We deliver Precision Medicine to patients through our commercially available and best in class genomic and immune-profiling tests.
- Cover all major solid tumors and hematopoietic malignancies
- Intuitive report designs provide results, matching therapies and trial options
- CLIA certified and NYS licensed
- Covered by traditional Medicare and Medicare Advantage plans, when medical necessity or other applicable clinical policy criteria are met
Predictive Testing Guide - Cancer Test Offerings for Precision Therapy
Biomarker Development from Discovery to CDx Commercialization
Increasingly, biomarkers play a key role in therapeutic development programs and have been shown to improve drug approval success rates by nearly 3-fold. Some biomarkers transition to become a companion diagnostic and as such, are a required test for prescribing a specific therapy. In this webinar, we focus on the development journey of a biomarker from early discovery, through clinical development and ultimately to an approved, commercially available companion diagnostic test. We present the example of and best practices discerned from a recently approved companion diagnostic assay which is used to assess the eligibility of patients with urothelial cancer for treatment with the newly approved FGFR kinase inhibitor, BALVERSA™ (erdafitinib).
Delivering on the Promise of Precision Medicine
Covance Chief Scientific Officer Steve Anderson speaks about the importance of partnerships in delivering on the promise of precision medicine.
LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer
Press Release: LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the availability of a newly-approved companion diagnostic by the U.S. Food and Drug Administration (FDA), the therascreen® FGFR mutation assay by RGQ RT-PCR, which is now available for ordering from LabCorp and its Integrated Oncology specialty laboratory.
Labcorp's Anjen Chenn speaks about FGFR molecular testing
At ASCO 2019, LabCorp's Senior Director for Molecular Oncology Anjen Chenn, MD Ph.D, speaks about FGFR testing solutions from QIAGEN and how it works. He also answers the question: Why does Day One Lab Readiness matter?
QIAGEN and LabCorp launch collaboration to provide Day-One access for patients to innovative companion diagnostics at the time of drug approvals
Hilden, Germany, and Germantown, Maryland, April 03, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a master service agreement with LabCorp® (NYSE: LH) to further accelerate the access of cancer patients to QIAGEN’s companion diagnostic products following regulatory approvals of drugs and their associated tests. [...]
Covance VP Thomas Turi on challenges with companion diagnostics
At ASCO 2019, Tom Turi speaks about companion diagnostics and the benefits for labs and patients gained from the Day One Lab Readiness program from QIAGEN.
Mission Bio Partners With LabCorp to Accelerate Targeted Drug Development with Single-Cell Genomics
Following earlier LabCorp strategic investment, Mission Bio single cell-sequencing technology will be used by LabCorp to support clinical trials, along with the evaluation of potential applications in clinical diagnostics and companion diagnostics development
Personalized Medicine - Promise or Potential?
LabCorp Chairman and CEO David P. King's Keynote Speech from 14th Annual Personalized Medicine Conference
Keynote Highlights from 14th Annual Personalized Medicine Conference
David P. King keynote highlights from 14th Annual Personalized Medicine Conference at Harvard Medical School
Covance and Definiens Collaborate to Integrate Digital Pathology into Precision Medicine Design and Development
Alliance intended to establish image analysis-enabled companion diagnostics as standard for comprehensive targeted therapies
Brian Caveney, LabCorp speaks about the Economics of Precision Medicine
LabCorp Chief Medical Officer Brian Caveney Speaks about the Economics of Precision Medicine at the Precision Medicine World Conference at Duke University
LabCorp and Unilabs Collaborate to Expand Global Reach of Precision Medicine Capabilities to Serve Patients, Physicians and Pharma
Collaboration creates global laboratory network for the development and commercialization of companion diagnostics
Companion Diagnostics: Changing the Way Patient Care is Provided
Immunotherapy has revolutionized the treatment of cancer by harnessing the power of the human immune system to combat the disease. These new therapies help prevent cancer cells from switching off the immune system in an effort to survive, thereby allowing the immune system to detect and destroy cancerous cells. [...]